Not applicableApproved For MarketingNCT04530994
What this trial is testing
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
Who this might be right for
Alagille Syndrome
Mirum Pharmaceuticals, Inc.